Jessica Allegretti

The gastrointestinal tract is a diverse and complex ecosystem shaped by continual interactions between host cells, nutrients, and the gut microbiota. Under homeostatic conditions, the human gut microbiota limits the growth of pathogenic bacteria and restricts the influence of resident pathobionts…

Handout [https://ddw.digitellinc…

BACKGROUND AND AIMS: A treat-to-target (TTT) strategy of striving for symptomatic and endoscopic remission is recommended for the management of inflammatory bowel diseases (IBD). Yet, real-world uptake of TTT strategies has been modest…

SOCIETY: AGA

BACKGROUND: Recurrent _Clostridioides difficile _infection (rCDI) is a debilitating disease associated with significant healthcare burden and low quality of life. The greatest risk factor for rCDI is a history of recurrence, although older age (≥65 years) and comorbidities also increase risk…

BACKGROUND: Gut dysbiosis is associated with persistent multi-system symptoms following SARS-CoV-2 infection, or post-acute COVID-19 syndrome (PACS). We performed a randomised controlled trial to assess the effects of gut microbiome modulation on alleviation of PACS symptoms…

The Phase 3 QUASAR Maintenance Study (NCT04033445) is a randomized-withdrawal, double-blind, placebo(PBO)-controlled, study that evaluated the efficacy and safety of maintenance treatment with subcutaneous (SC) guselkumab (GUS), an IL-23p19 subunit antagonist, in patients (pts) with moderately to s…

Background: We compared real-world outcomes of upadacitinib (upa) vs tofacitinib (tofa) for ulcerative colitis (UC) through 52 weeks…

SOCIETY: AGA This session will feature cutting-edge research on the multifaceted aspects of Clostridioides difficile colitis, presenting the latest findings in pathogenesis and innovative therapeutic approaches. Attendees will gain valuable insights into the molecular and immunological aspects of C…